Literature DB >> 2019372

Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate.

H Z Park1, S P Lee, A L Schy.   

Abstract

Ceftriaxone, a third-generation cephalosporin, is partially excreted into bile. With its clinical use, the formation of gallbladder sludge detected by ultrasonography has been reported. Four surgical specimens were examined and no gallstones were found. Instead, fine precipitates of 20-250 microns were present. Microscopically, there was a small number of cholesterol monohydrate crystals and bilirubin granules among an abundant amount of granular-crystalline material that was not morphologically cholesterol monohydrate crystals. The chemical composition of the precipitates (n = 4) was determined. There was a small amount of cholesterol (1.7% +/- 0.8%) and bilirubin (13.9% +/- 0.74%). The major component of the precipitate was a residue. On further analysis using thin-layer chromatography, high-performance liquid chromatography, and electron microprobe analysis, the residue was identified as a calcium salt of ceftriaxone. The residue also had identical crystal morphology and chromatographic elution profile as authentic calcium-ceftriaxone standards. It is concluded that ceftriaxone, after excretion and being concentrated in the gallbladder bile, can form a precipitate. The major constituent has been identified as a ceftriaxone-calcium salt.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019372     DOI: 10.1016/0016-5085(91)90667-a

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

1.  Ceftriaxone associated nephrolithiasis: a prospective study in 284 children.

Authors:  Masoumeh Mohkam; Abdollah Karimi; Atoosa Gharib; Hamid Daneshmand; Alireza Khatami; Nozar Ghojevand; Mostafa Sharifian
Journal:  Pediatr Nephrol       Date:  2007-01-17       Impact factor: 3.714

2.  Vitamin K supplementation during prophylactic use of cefoperazone in urologic surgery.

Authors:  S D Rockoff; M J Blumenfrucht; R J Irwin; R H Eng
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

3.  Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis.

Authors:  Sendia Kim; Kathleen M Gura; Mark Puder
Journal:  Pediatr Surg Int       Date:  2006-02-17       Impact factor: 1.827

4.  A symptomatic child with ceftriaxone-associated biliary pseudolithiasis.

Authors:  Naoki Kutuya; Yutaka Ozaki; Tadaharu Okazaki
Journal:  J Med Ultrason (2001)       Date:  2008-09-19       Impact factor: 1.314

5.  Increasing urinary calcium excretion after ceftriaxone and cephalothin therapy in adults: possible association with urolithiasis.

Authors:  Alper Otunctemur; Emin Ozbek; Emre Can Polat; Mustafa Cekmen; Murat Dursun; Suleyman Sami Cakir
Journal:  Urolithiasis       Date:  2013-12-06       Impact factor: 3.436

6.  Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children.

Authors:  Z Avci; A Koktener; N Uras; F Catal; A Karadag; O Tekin; H Degirmencioglu; E Baskin
Journal:  Arch Dis Child       Date:  2004-11       Impact factor: 3.791

7.  Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis.

Authors:  Hanna Alemayehu; Amita A Desai; Priscilla Thomas; Susan W Sharp; Shawn D St Peter
Journal:  Pediatr Surg Int       Date:  2014-01-28       Impact factor: 1.827

Review 8.  Drug-induced gallbladder disease. Incidence, aetiology and management.

Authors:  P P Michielsen; H Fierens; Y M Van Maercke
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

9.  Biliary pseudolithiasis in a child associated with 2 days of ceftriaxone therapy.

Authors:  C Blais; R Duperval
Journal:  Pediatr Radiol       Date:  1994

10.  Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction.

Authors:  Aya Imafuku; Naoki Sawa; Akinari Sekine; Masahiro Kawada; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Noriko Hayami; Jyunichi Hoshino; Yoshifumi Ubara; Kenmei Takaichi
Journal:  Clin Exp Nephrol       Date:  2017-10-12       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.